| 1. |
- Hjalmarsson, Erik, et al.
(författare)
-
Dialectical behaviour therapy for borderline personality disorder among adolescents and young adults : Pilot study, extending the research findings in new settings and cultures
- 2008
-
Ingår i: Clinical Psychologist. - : Wiley-Blackwell. - 1328-4207 .- 1742-9552. ; 12:1, s. 18-29
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this paper was to investigate the feasibility and impact of dialectical behaviour therapy (DBT) for patients with borderline personality disorder (BPD) in a clinical outpatient setting. Eighteen clinicians were trained and supervised in using DBT. Twenty-seven female patients were assessed on a number of variables before the treatment, as well as 5 and 12 months after the start of the DBT. Despite some barriers, DBT could be implemented successfully, and the professionals reported increased competence 1 year after the start of the therapy. Low treatment dropout rates suggested that DBT was well accepted by the patients. One year after the start of treatment, the patients reported significant decrease on most variables measuring psychological distress and number of parasuicidal behaviours. The study provides preliminary support for the feasibility and impact of DBT in the outpatient treatment of BPD in a cultural setting outside the United States.
|
|
| 2. |
- Johnson, Mats, 1956, et al.
(författare)
-
Fatty acids in ADHD: plasma profiles in a placebo-controlled study of Omega 3/6 fatty acids in children and adolescents.
- 2012
-
Ingår i: Attention Deficit and Hyperactivity Disorders. - : Springer Science and Business Media LLC. - 1866-6116 .- 1866-6647. ; 4:4, s. 199-204
-
Tidskriftsartikel (refereegranskat)abstract
- The aim of this study was to assess baseline levels and changes in plasma fatty acid profiles in children and adolescents with ADHD, in a placebo-controlled study with Omega 3/6 supplementation, and to compare with treatment response. Seventy-five children and adolescents aged 8-18years with DSM-IV ADHD were randomized to 3months of Omega 3/6 (Equazen eye q) or placebo, followed by 3months of open phase Omega 3/6 for all. n-3, n-6, n-6/n-3 ratio, EPA and DHA in plasma were measured at baseline, 3 and 6months. Subjects with more than 25% reduction in ADHD symptoms were classified as responders. At baseline, no significant differences in mean fatty acid levels were seen across active/placebo groups or responder/non-responder groups. The 0-3month changes in all parameters were significantly greater in the active group (p<0.01). Compared to non-responders, the 6-month responders had significantly greater n-3 increase at 3months and decrease in n-6/n-3 ratio at 3 and 6months (p<0.05). Omega 3/6 supplementation had a clear impact on fatty acid composition of plasma phosphatidyl choline in active versus placebo group, and the fatty acid changes appear to be associated with treatment response. The most pronounced and long-lasting changes for treatment responders compared to non-responders were in the n-6/n-3 ratio.
|
|
| 3. |
- Johnson, Mats, 1956, et al.
(författare)
-
Long-term medication for ADHD and development of cognitive functions in children and adolescents
- 2021
-
Ingår i: Journal of Psychiatric Research. - : Elsevier BV. - 0022-3956. ; 142, s. 204-209
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Long-term effects of ADHD medication on cognitive functions are not well known. This study investigates development of cognitive functions and ADHD symptoms on well-controlled medication for 1 year in children and adolescents. Study design: This study is part of an ongoing open uncontrolled trial of long-term medication for ADHD in children and adolescents aged 6-18 years with any form of ADHD, and frequently comorbid autism spectrum disorder (ASD, 29%) or autistic traits (24%). Other comorbidities were oppositional defiant disorder, dyslexia/ language disorder, borderline intellectual functioning, developmental coordination disorder. This analysis includes 87 participants (61 boys, 26 girls) who completed Wechsler tests at baseline and after 12 months. ADHD symptoms were investigator-rated on the ADHD Rating Scale-IV at the same time points. Results: The whole group of children and adolescents showed significant improvements in Wechsler Full Scale IQ (FSIQ, mean at baseline 92.6, at 12 months 97.95), and on the Index Scales Verbal Comprehension, Working Memory and Processing Speed, after one year of well-controlled ADHD medication. Comorbid dyslexia/language impairment predicted a larger rise in FSIQ, but not gender, ADHD presentation or comorbid ASD. Robust improvements in ADHD symptoms were observed (mean ADHD-Rating Scale score at baseline 34.6, and at 12 months 18.3). Conclusions: Cognitive test scores and ADHD symptoms were improved on well-controlled medication for 1 year in children and adolescents with ADHD, autism and other comorbidities. The main study limitation is the open uncontrolled trial design.
|
|
| 4. |
- Svensson, Jakob, et al.
(författare)
-
2023 års ekonomipris till Claudia Goldin
- 2023
-
Ingår i: Ekonomisk Debatt. - 0345-2646. ; 51:8, s. 38-45
-
Forskningsöversikt (övrigt vetenskapligt/konstnärligt)abstract
- Kungl. Vetenskapsakademien har beslutat dela ut årets ekonomipris till Claudia Goldin (verksam vid Harvard University) ”för att ha förbättrat vår förståelse av kvinnors arbetsmarknadsutfall”. Hon var först med att ge en helhetsbild av kvinnors inkomster och deltagande på arbetsmarknaden genom århundradena. Forskningen belyser drivkrafterna bakom förändringarna och pekar på de huvudsakliga orsakerna till de skillnader mellan könen som kvarstår än i dag.
|
|
